[1]杨春睿 杨欢 董珊珊 李婷 白彝华 何振坤.Ⅳ型心肾综合征发病机制研究进展[J].心血管病学进展,2025,(10):902.[doi:10.16806/j.cnki.issn.1004-3934.2025.10.009]
　YANG Chunrui,YANG Huan,DONG Shanshan,et al.Pathogenesis of Type Cardiorenal Syndrome[J].Advances in Cardiovascular Diseases,2025,(10):902.[doi:10.16806/j.cnki.issn.1004-3934.2025.10.009]
点击复制

Ⅳ型心肾综合征发病机制研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年10期
页码:
902
栏目:
综述
出版日期:
2025-10-25

文章信息/Info

Title:
Pathogenesis of Type Cardiorenal Syndrome
作者:
杨春睿 杨欢 董珊珊 李婷 白彝华 何振坤
(昆明医科大学第二附属医院,云南 昆明 650000)
Author(s):
YANG Chunrui;  YANG Huan;  DONG Shanshan;  LI Ting;  BAI Yihua;  HE Zhenkun
(Department of Nephrology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650000, Yunnan, China)
关键词:
心肾综合征; 尿毒症毒素; 慢性肾脏病矿物质骨代谢紊乱; 慢性肾病贫血; 微RNA
Keywords:
Cardiorenal syndrome; Uremic toxins; Chronic kidney disease-mineral and bone disorder; Anemia of chronic renal disease; MicroRNA
DOI:
10.16806/j.cnki.issn.1004-3934.2025.10.009
摘要:
Ⅳ型心肾综合征 （CRS）发病率高且预后较差，如何有效防治一直是医学界的重大挑战。其发病机制涉及尿毒症毒素蓄积致使肠道菌群失调导致硫酸吲哚酚、三甲胺-N-氧化物的进一步蓄积和短链脂肪酸的减少，血流动力学和神经体液调节失衡，慢性肾脏病矿物质骨代谢紊乱以及慢性肾病贫血。尿毒症心肌病的形成又进一步加重心血管损伤，微RNA遗传调控致病机制的发现为Ⅳ型CRS发病机制的研究提供了新的视野。现综述Ⅳ型CRS发病机制的最新研究进展，旨在通过揭示潜在的治疗靶点为疾病防治提供新的策略和选择。
Abstract:
Type Ⅳ cardiorenal syndrome (CRS) has a high prevalence and poor prognosis, and how to effectively prevent and treat it has been a major challenge in the medical field. The pathogenesis involves accumulation of uremic toxins resulting in intestinal flora dysbiosis leading to further accumulation of indoxyl sulfate, trimethylamine-N-oxide, and reduction of short-chain fatty acid, hemodynamic and neurohumoral imbalance, chronic kidney disease-mineral and bone disorder, and anemia of chronic renal disease. The development of uremic cardiomyopathy further exacerbates cardiovascular injury, and the discovery of the pathogenic mechanism of microRNA genetic regulation has provided a new vision for the study of the pathogenesis of type Ⅳ CRS. This review summarizes the latest research progress on the pathogenesis of type Ⅳ CRS , aiming to provide new strategies and options for disease prevention and treatment by revealing potential therapeutic targets

参考文献/References:

[1] Ronco C,McCullough P,Anker SD,et al. Cardio-renal syndromes:report from the consensus conference of the Acute Dialysis Quality Initiative[J]. Eur Heart J,2010,31(6):703-711.

[2] United States Renal Data System. 2020 USRDS Annual Data Report:Epidemiology of kidney disease in the United States (National Institutes of Health,National Institute of Diabetes and Digestive and Kidney Diseases,2020) [EB/OL]. Bethesda:MD,(2020)[2024-04-21]. https://usrds-adr.niddk.nih.gov/.

[3] Lim YJ,Sidor NA,Tonial NC,et al. Uremic toxins in the progression of chronic kidney disease and cardiovascular disease:mechanisms and therapeutic targets[J]. Toxins (Basel),2021,13(2):142.

[4] Rysz J,Franczyk B,?awiński J,et al. The impact of CKD on uremic toxins and gut microbiota[J]. Toxins (Basel),2021,13(4):252.

[5] He M,Wei W,Zhang Y,et al. Gut microbial metabolites SCFAs and chronic kidney disease[J]. J Transl Med,2024,22:172.

[6] Yamaguchi K,Yisireyili M,Goto S,et al. Indoxyl sulfate activates NLRP3 inflammasome to induce cardiac contractile dysfunction accompanied by myocardial fibrosis and hypertrophy[J]. Cardiovasc Toxicol,2022,22(4):365-377.

[7] Savira F,Kompa AR,Magaye R,et al. Apoptosis signal-regulating kinase 1 inhibition reverses deleterious indoxyl sulfate-mediated endothelial effects[J]. Life Sci,2021,272:119267.

[8] Yamagami F,Tajiri K,Yumino D,et al. Uremic toxins and atrial fibrillation:mechanisms and therapeutic implications[J]. Toxins (Basel),2019,11(10):597.

[9] van Ham WB,Cornelissen CM,Polyakova E,et al. Pro-arrhythmic potential of accumulated uremic toxins is mediated via vulnerability of action potential repolarization[J]. Int J Mol Sci,2023,24(6):5373.

[10] Karpushev AV,Mikhailova VB,Klimenko ES,et al. SGLT2 inhibitor Empagliflozin modulates ion channels in adult zebrafish heart[J]. Int J Mol Sci,2022,23(17):9559.

[11] Tang WHW,Wang Z,Levison BS,et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk[J]. N Engl J Med,2013,368(17):1575-1584.

[12] Zhang Y,Wang Y,Ke B,et al. TMAO:how gut microbiota contributes to heart failure[J]. Transl Res,2021,228:109-125.

[13] Wu K,Yuan Y,Yu H,et al. The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice[J]. Blood,2020,136(4):501-515.

[14] Shi W,Huang Y,Yang Z,et al. Reduction of TMAO level enhances the stability of carotid atherosclerotic plaque through promoting macrophage M2 polarization and efferocytosis[J]. Biosci Rep,2021,41(6):BSR20204250.

[15] Wang Z,Roberts AB,Buffa JA,et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis[J]. Cell,2015,163(7):1585-1595.

[16] Xu J,Moore BN,Pluznick JL. Short-chain fatty acid receptors and blood pressure regulation:Council on Hypertension Mid-Career Award for Research Excellence 2021[J]. Hypertension,2022,79(10):2127-2137.

[17] Pluznick JL,Protzko RJ,Gevorgyan H,et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation[J]. Proc Natl Acad Sci U S A,2013,110(11):4410-4415.

[18] Datta S,Pasham S,Inavolu S,et al. Role of gut microbial metabolites in cardiovascular diseases—Current Insights and the road ahead[J]. Int J Mol Sci,2024,25(18):10208.

[19] Smith PM,Howitt MR,Panikov N,et al. The microbial metabolites,short-chain fatty acids,regulate colonic treg cell homeostasis[J]. Science,2013,341(6145):569-573.

[20] Yan J,Pan Y,Shao W,et al. Beneficial effect of the short-chain fatty acid propionate on vascular calcification through intestinal microbiota remodelling[J]. Microbiome,2022,10(1):195.

[21] Zeder K,Siew ED,Kovacs G,et al. Pulmonary hypertension and chronic kidney disease:prevalence,pathophysiology and outcomes[J]. Nat Rev Nephrol,2024,20(11):742-754.

[22] Matsushita K,Ballew SH,Wang AYM,et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease[J]. Nat Rev Nephrol,2022,18(11):696-707.

[23] di Lullo L,Reeves PB,Bellasi A,et al. Cardiorenal syndrome in acute kidney injury[J]. Semin Nephrol,2019,39(1):31-40.

[24] van den Eynde J,Jacquemyn X,Cloet N,et al. Arteriovenous fistulae in chronic kidney disease and the heart:physiological,histological,and transcriptomic characterization of a novel rat model[J]. J Am Heart Assoc,2022,11(20):e027593.

[25] Cozzolino M,Ciceri P,Galassi A,et al. The key role of phosphate on vascular calcification[J]. Toxins (Basel),2019,11(4):213.

[26] Carrillo-López N,Martínez-Arias L,Alonso-Montes C,et al. The receptor activator of nuclear factor κΒ ligand?receptor leucine-rich repeat-containing G-protein-coupled receptor 4?contributes to parathyroid hormone-induced vascular calcification[J]. Nephrol Dial Transplant,2021,36(4):618-631.

[27] Arase H,Yamada S,Tanaka S,et al. Association between plasma intact parathyroid hormone levels and the prevalence of atrial fibrillation in patients with chronic kidney disease—The Fukuoka Kidney Disease Registry Study[J]. Circ J,2020,84(7):1105-1111.

[28] Trevisan C,Rossi A,Curreri C. Increased parathyroid hormone concentration as a biomarker of atrial fibrillation in severe aortic stenosis:Editorial comment[J]. Kardiol Pol,2024,82(11):1055-1056.

[29] Han X,Cai C,Xiao Z,et al. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice[J]. J Mol Cell Cardiol,2020,138:66-74.

[30] Ishigami J,Grams ME,Naik RP,et al. Hemoglobin,albuminuria,and kidney function in cardiovascular risk:the ARIC (Atherosclerosis Risk in Communities) Study[J]. J Am Heart Assoc,2018,7(2):e007209.

[31] Packer M. Mutual antagonism of hypoxia-inducible factor isoforms in cardiac,vascular,and renal disorders[J]. JACC Basic Transl Sci,2020,5(9):961-968.

[32] Zhao Y,Xiong W,Li C,et al. Hypoxia-induced signaling in the cardiovascular system:pathogenesis and therapeutic targets[J]. Signal Transduct Target Ther,2023,8(1):431.

[33] Buliga-Finis ON,Ouatu A,Tanase DM,et al. Managing Anemia:point of convergence for heart failure and chronic kidney disease?[J]. Life (Basel),2023,13(6):1311.

[34] Dobre MA,Ahlawat S,Schelling JR. Chronic kidney disease associated cardiomyopathy:recent advances and future perspectives[J]. Curr Opin Nephrol Hypertens,2024,33(2):203-211.

[35] Amann K,Ritz E. The heart in renal failure:morphological changes of the myocardium—New insights[J]. J Clin Basic Cardiol,2001,4:109-113.

[36] van Ham WB,Cornelissen CM,van Veen TAB. Uremic toxins in chronic kidney disease highlight a fundamental gap in understanding their detrimental effects on cardiac electrophysiology and arrhythmogenesis[J]. Acta Physiol (Oxf),2022,236(3):e13888.

[37] Munguia-Galaviz FJ,Gutierrez-Mercado YK,Miranda-Diaz AG,et al. Cardiac transcriptomic changes induced by early CKD in mice reveal novel pathways involved in the pathogenesis of Cardiorenal syndrome type 4[J]. Heliyon,2024,10(6):e27468.

[38] Chade AR,Eirin A. Cardiac micro-RNA and transcriptomic profile of a novel swine model of chronic kidney disease and left ventricular diastolic dysfunction[J]. Am J Physiol Heart Circ Physiol,2022,323(4):H659-H669.

[39] Yu F,Peng Z,Gao N,et al. Sinomenine attenuates uremia vascular calcification by miR-143-5p[J]. Sci Rep,2025,15(1):1798.

[40] Di J,Yang M,Zhou H,et al. MicroRNA-21-containing microvesicles from tubular epithelial cells promote cardiomyocyte hypertrophy[J]. Ren Fail,2021,43(1):391-400.

相似文献/References:

[1]金亮丽 王治.现代医学影像学在心肾综合征中的应用进展[J].心血管病学进展,2021,(7):645.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.017]
　JIN Liangli,WANG Zhi.Application Progress of Modern Medical Imaging Technology in Cardiorenal Syndrome[J].Advances in Cardiovascular Diseases,2021,(10):645.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.017]
[2]薛超 吴弘.脑利尿钠肽及N末端脑钠肽前体在心肾综合征患者中的应用进展[J].心血管病学进展,2023,(6):546.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.015]
　XUE Chao,WU Hong.Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Application in Cardiorenal Syndrome[J].Advances in Cardiovascular Diseases,2023,(10):546.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.015]
[3]张严 宋可欣 姚朱华.钠-葡萄糖共转运蛋白2抑制剂对心肾综合征获益机制的研究进展[J].心血管病学进展,2024,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.002]
　ZHANG Yan,SONG Kexin,YAO Zhuhua.Advances in the Beneficial Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor in Cardiorenal Syndrome[J].Advances in Cardiovascular Diseases,2024,(10):389.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.002]
[4]白慧茹 庞建中.心血管-肾脏-代谢综合征的提出与临床现状[J].心血管病学进展,2025,(12):1071.[doi:10.16806/j.cnki.issn.1004-3934.2025.12.004]
　BAI Huiru,PANG Jianzhong.Proposal and Clinical Status of Cardiovascular-Kidney-Metabolic Syndrome[J].Advances in Cardiovascular Diseases,2025,(10):1071.[doi:10.16806/j.cnki.issn.1004-3934.2025.12.004]

更新日期/Last Update: 2026-01-16